Gatskikh I V, Veselova O F, Brikman I N, Shalda T P, Varygina E L, Kuznetsov M N, Shul'min A V, Petrova M M
Eksp Klin Farmakol. 2015;78(11):21-5.
Authors studied the efficacy of cytoflavin in the correction of cognitive impairment in patients with type 2 diabetes mellitus and the drug influence on the level of brain-derived neurotrophic factor (BDNF) in blood serum. The results of treatment and examination of 60 patients with type 2 diabetes diagnosis have been analyzed. The majority (49-81.6%) of patients initially exhibited light (35-71.4%) and moderate (14-28.6%) cognitive impairments. All patients received standard treatment with oral antidiabetic drugs: metformin monotherapy (26 patients or 43.3%) and combined therapy (metformin + gliclazide, 34 patients or 56.6%). In addition, 30 patients (main group) received a complex metabolic drug cytoflavin daily intravenously (10 mL in 200 mL of 0.9% sodium chloride) for 10 days with transition to the tablet form in a dose of 2 tablets (with 0.6 succinic acid, 0.1 riboxin, 0:05 nicotinamide, 0.01 riboflavin) two times a day for 25 days. The control group (n = 30) consisted of patients who received only basic hypoglycemic therapy. The inclusion of cytoflavin in the scheme of complex treatment of patients with type 2 diabetes ensured a more effective correction of cognitive impairments as compared to the group receiving basic therapy. This is confirmed by the results of neuropsychological testing (MoCA test) and improved optical and spatial activity, attention, abstract thinking, and memory on the average by 14.2% compared to the value before treatment (p < 0.01) in patients of standard treatment group. Patients in the control group showed positive dynamics of same parameters amounted on the average to 7.9%. The study of BDNF in the blood serum showed a significant increase in this index over time in patients who have received cytoflavin (from 1475.13 + 421.26 pg/ml to 1839.44 + 494.78 pg/mL, p < 0.01) in contrast to the control group (1625.41 + 322.53 pg/mL to 1592.04 + 373.47 pg/mL) and revealed positive correlation between the MoCA test and BDNF level in the blood serum for optico-spatial activity (r = 0.589, p < 0.01), naming (animals) (r = 0.346, p < 0.01), attention (r = 0.401, p < 0.01), memory (r=0.595, p< 0.01) and total rating in the test (r = 0.708, p < 0.01). In addition, a negative correlation was revealed between the level of carbohydrate metabolism (HbA1c) and BDNF levels in the blood serum (r = -0.494, p < 0.01) in both groups.
作者研究了细胞黄素对2型糖尿病患者认知功能障碍的纠正效果以及该药物对血清中脑源性神经营养因子（BDNF）水平的影响。分析了60例2型糖尿病确诊患者的治疗和检查结果。大多数患者（49例，占81.6%）最初表现为轻度（35例，占71.4%）和中度（14例，占28.6%）认知功能障碍。所有患者均接受口服降糖药的标准治疗：二甲双胍单药治疗（26例患者，占43.3%）和联合治疗（二甲双胍+格列齐特，3例患者，占56.6%）。此外，30例患者（主要组）每天静脉注射复合代谢药物细胞黄素（10 mL加入200 mL 0.9%氯化钠溶液中），持续10天，之后转为片剂形式，剂量为每日2片（含0.6琥珀酸、0.1核糖核酸、0.05烟酰胺、0.01核黄素），持续25天。对照组（n = 30）由仅接受基础降糖治疗的患者组成。与接受基础治疗的组相比，在2型糖尿病患者的综合治疗方案中加入细胞黄素可更有效地纠正认知功能障碍。标准治疗组患者的神经心理学测试（MoCA测试）结果以及视觉和空间活动、注意力、抽象思维和记忆力较治疗前平均提高了14.2%（p < 0.01），证实了这一点。对照组患者相同参数的平均积极变化为7.9%。血清中BDNF的研究表明，接受细胞黄素治疗的患者该指标随时间显著增加（从1475.13 + 421.26 pg/ml增至1839.44 + 494.78 pg/mL，p < 0.01），而对照组则从1625.41 + 322.53 pg/mL降至1592.04 + 373.47 pg/mL），并且血清中BDNF水平与MoCA测试的视觉空间活动（r = 0.589，p < 0.01）、命名（动物）（r = 0.346，p < 0.01）、注意力（r = 0.401，p < 0.01）、记忆力（r = 0.595，p < 0.01）以及测试总评分（r = 0.708，p < 0.01）之间呈正相关。此外，两组中碳水化合物代谢水平（糖化血红蛋白）与血清中BDNF水平之间均呈负相关（r = -0.494，p < 0.01）。
